Cronos GroupCRON 86 Current Ratio is 21.87 as of Mar. 2026, which is 46% above its 10-year median of 14.98. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, Cronos Group ranks better than 97.99% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cronos Group's current ratio for the quarter that ended in Mar. 2026 was 21.87.
Cronos Group has a current ratio of 21.87. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cronos Group's Current Ratio or its related term are showing as below:
CRON'
s Current Ratio Range Over the Past 10 Years
Min: 1.04 Med: 14.98 Max: 52.75
Current: 21.87
During the past 12 years, Cronos Group's highest Current Ratio was 52.75. The lowest was 1.04. And the median was 14.98.
CRON's Current Ratio is ranked better than 97.99% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs CRON: 21.87
Cronos Group (NAS:CRON) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cronos Group Current Ratio Related Terms
Cronos Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Cronos Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cronos Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a Current Ratio of 21.87 as of Mar. 2026. This is 46% above median its historical median of 14.98. Over the past decade, Cronos Group's Current Ratio has ranged from 1.04 to 52.75. According to the industry distribution chart, Cronos Group ranks #20 out of 997 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Cronos Group's Current Ratio too high?
Cronos Group's current Current Ratio of 21.87 is 46% above median its 10-year median of 14.98. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 52.75. The Drug Manufacturers industry median Current Ratio is 2.00. Cronos Group's value of 21.87 is 993.5% above this industry median. Based on the distribution chart, Cronos Group ranks #20 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #20 out of 997 companies for Current Ratio. This places Cronos Group in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Cronos Group's value of 21.87 is 993.5% above this benchmark. Historically, Cronos Group's own Current Ratio has ranged from 1.04 to 52.75 over the past decade. While the company's 10-year median is 14.98 vs. the industry median of 2.00, Cronos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Current Ratio of 21.87 is 993.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Current Ratio is 21.87, which is 46% above median its own 10-year median of 14.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.86 — trading 18.5% below its estimated fair value. The current Current Ratio is 21.87, which is 46% above median its 10-year median of 14.98 and 993.5% above the Drug Manufacturers industry median of 2.00. Cronos Group's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cronos Group (CRON), the current Current Ratio is 21.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.86 is trading 18.5% below its estimated GF Value™ of $3.51.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
Current Ratio: 21.87 (46% above median its 10-year median of 14.98)
GF Value™: $3.51 vs. price of $2.86 (18.5% below fair value)
Industry Position: 993.5% above the Drug Manufacturers median (#20 of 997)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
